Kevin McKinski
Research Subjects
Kevin McKinski has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Mary Birchler
Precision Medicine – Biomarker & Bioanalytical Platforms (BBP), GSK, Collegeville, PA, USA
2 shared publications- Andria Culbert1 shared publication
Bin Chen
Department of Pharmaceutical Sciences, Saint Joseph’s University, Philadelphia College of Pharmacy, Philadelphia, USA
1 shared publication- Chenmei Hou1 shared publication
Christopher Evans
Bioanalysis, Immunogenicity & Biomarkers, GlaxoSmithKline, Collegeville, PA, 19426, USA
1 shared publication- Ciara Seal1 shared publication
Latest Publications
- 20 November 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 29 (1)
A Strategic Framework for Optimized Bioanalytical Outsourcing: An Integrated Approach to Assay Development, CRO Selection, and Performance Governance
- 20 November 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 29 (1)
A Strategic Framework for Optimized Bioanalytical Outsourcing: An Integrated Approach to Assay Development, CRO Selection, and Performance Governance
- Open Access
- 23 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Quantitative immunohistochemistry and the use of cellular calibrators for HER2 receptor number determination
It is suggested that high error rates in clinical IHC compared to other laboratory disciplines are due to a lack of traceable analytic standards with quantitative controls. Quantitative controls can be achieved by implementing calibrators into IHC workflows, but recently published approaches offer little discussion about what the ideal calibrator should look like. Here, we detail an IHC method that utilizes cellular calibrators to determine the average number of HER2 receptors in tumor cells of breast cancer tissue. Electrochemiluminescent immunoassay and flow cytometry were used to establish nominal HER2 amounts in the cellular calibrators. The quantitated number of HER2 receptors and associated 4B5 scores from commercially sourced breast cancer tumors were compared. The results were discordant, indicating differences in analytical performance. Cells are ideal calibrators for IHC because the antigens they express are structurally and functionally representative of the endogenous analyte being measured. They can also be stained and analyzed identically to tissues, and are easily cultured, expanded, and manipulated. However, novel methods for labeling cells with fixed amounts of proteins are needed. In addition, standards for validation of quantitative IHC methods should be developed and their clinical utility must be demonstrated.
- 23 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessQuantitative immunohistochemistry and the use of cellular calibrators for HER2 receptor number determination
It is suggested that high error rates in clinical IHC compared to other laboratory disciplines are due to a lack of traceable analytic standards with quantitative controls. Quantitative controls can be achieved by implementing calibrators into IHC workflows, but recently published approaches offer little discussion about what the ideal calibrator should look like. Here, we detail an IHC method that utilizes cellular calibrators to determine the average number of HER2 receptors in tumor cells of breast cancer tissue. Electrochemiluminescent immunoassay and flow cytometry were used to establish nominal HER2 amounts in the cellular calibrators. The quantitated number of HER2 receptors and associated 4B5 scores from commercially sourced breast cancer tumors were compared. The results were discordant, indicating differences in analytical performance. Cells are ideal calibrators for IHC because the antigens they express are structurally and functionally representative of the endogenous analyte being measured. They can also be stained and analyzed identically to tissues, and are easily cultured, expanded, and manipulated. However, novel methods for labeling cells with fixed amounts of proteins are needed. In addition, standards for validation of quantitative IHC methods should be developed and their clinical utility must be demonstrated.
- 20 December 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (1) , 17-29
Comparison of highly sensitive, multiplex immunoassay platforms for streamlined clinical cytokine quantification
Selecting the optimal platforms to quantitate cytokines is challenging due to varying performance and the plethora of options available. To compare performance of three highly sensitive, multiplex assays on three different platforms - MSD S-plex, Olink Target 48, and Quanterix SP-X - to MSD V-plex which is widely used for quantitative cytokine assay. Serum and stimulated plasma samples were analyzed across each platform. The proportion of quantifiable samples was compared for each analyte and correlation analyses were performed to relate the data. For MSD S-plex, parallelism and antibody pair knockdown experiments gauged specificity of the kit. MSD S-plex was the most sensitive multiplex platform followed by Olink Target 48, Quanterix SP-X, and MSD V-plex. Concentrations across platforms differed greatly for some cytokines, but all platforms showed strong correlation. Results for MSD S-plex were confirmed by parallelism and knockdown. MSD S-plex should be a priority platform for ultra-sensitive assay. Olink Target 48 offers an enticing combination of sensitivity and multiplex capability that warrants consideration when many cytokines require quantitation. MSD V-plex, MSD S-plex and Olink quantitative assays offer high utility across drug development programs, but fit-for-purpose performance should be assessed on a per-analyte basis.
- 20 December 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (1) , 17-29
Comparison of highly sensitive, multiplex immunoassay platforms for streamlined clinical cytokine quantification
Selecting the optimal platforms to quantitate cytokines is challenging due to varying performance and the plethora of options available. To compare performance of three highly sensitive, multiplex assays on three different platforms - MSD S-plex, Olink Target 48, and Quanterix SP-X - to MSD V-plex which is widely used for quantitative cytokine assay. Serum and stimulated plasma samples were analyzed across each platform. The proportion of quantifiable samples was compared for each analyte and correlation analyses were performed to relate the data. For MSD S-plex, parallelism and antibody pair knockdown experiments gauged specificity of the kit. MSD S-plex was the most sensitive multiplex platform followed by Olink Target 48, Quanterix SP-X, and MSD V-plex. Concentrations across platforms differed greatly for some cytokines, but all platforms showed strong correlation. Results for MSD S-plex were confirmed by parallelism and knockdown. MSD S-plex should be a priority platform for ultra-sensitive assay. Olink Target 48 offers an enticing combination of sensitivity and multiplex capability that warrants consideration when many cytokines require quantitation. MSD V-plex, MSD S-plex and Olink quantitative assays offer high utility across drug development programs, but fit-for-purpose performance should be assessed on a per-analyte basis.
- Open Access
- 27 June 2021
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 12 (2) , 317-323
Orthogonal quantification of soluble inducible T-cell costimulator (ICOS) in healthy and diseased human serum
- 27 June 2021
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 12 (2) , 317-323
Open AccessOrthogonal quantification of soluble inducible T-cell costimulator (ICOS) in healthy and diseased human serum